{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:38:41Z","timestamp":1778913521304,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T00:00:00Z","timestamp":1625270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600299"],"award-info":[{"award-number":["81600299"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study was performed to investigate the clinical significance of combined evaluation of both coronary artery disease (CAD) and high-sensitivity cardiac troponin T (hs-cTnT) for prediction of major adverse cardiovascular events (MACEs) in patients with hypertrophic cardiomyopathy (HCM).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed clinical evaluations, including coronary artery imaging and hs-cTnT measurement, in 162 patients with HCM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patients were followed up for a median period of 3.7\u00a0years (interquartile range 2.4\u20135.6\u00a0years; total of 632.3 person-years [PYs]), during which time MACEs occurred in 24 (14.8%) patients. The incidence of MACEs was 6.4 and 2.7 per 100 PYs for patients with CAD and normal coronary arteries, respectively; similarly, the incidence was 5.8 and 2.1 per 100 PYs in patients with an elevated hs-cTnT concentration (&gt;\u200914.0\u00a0ng\/L) and a normal hs-cTnT concentration, respectively. The multivariate analysis suggested that CAD and an elevated hs-cTnT concentration tended to be positively associated with MACEs. When the groups were allocated according to these two markers, the patients were divided into four groups, which further improved the predictive values. The incidence of MACEs was 10.4 per 100 PYs in the CAD and elevated hs-cTnT group, which was much higher than the incidence in all other groups (range, 2.0\u20133.5 per 100 PYs). With the normal coronary arteries and normal hs-cTnT group serving as a reference, the adjusted hazard ratio was 5.0 (95% confidence interval 1.0\u201323.8; <jats:italic>P<\/jats:italic>\u2009=\u20090.046) for the CAD and elevated hs-cTnT group. In addition, the subgroup analysis showed similar findings among the patients without severe CAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with HCM, combined evaluation of both CAD and hs-cTnT might facilitate more reliable prediction of MACEs than evaluation of a single marker. These may serve as clinically useful markers to guide risk management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-02135-x","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T09:02:49Z","timestamp":1625302969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combined evaluation of\ncoronary artery disease and high-sensitivity cardiac troponin T for\nprediction of adverse events in\npatients with hypertrophic cardiomyopathy"],"prefix":"10.1186","volume":"21","author":[{"given":"Hang","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huay Cheem","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-5754","authenticated-orcid":false,"given":"Sen","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"key":"2135_CR1","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Authors\/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379.","journal-title":"Eur Heart J"},{"key":"2135_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"2135_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655\u201368.","journal-title":"N Engl J Med"},{"key":"2135_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.jacc.2015.03.516","volume":"65","author":"P Spirito","year":"2015","unstructured":"Spirito P. The dawn of a better day for patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1929\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"2135_CR5","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.117.027738","volume":"135","author":"BJ Maron","year":"2017","unstructured":"Maron BJ, Maron MS, Rowin EJ. Perspectives on the overall risks of living with hypertrophic cardiomyopathy. Circulation. 2017;135:2317\u20139.","journal-title":"Circulation"},{"key":"2135_CR6","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.jacc.2011.08.040","volume":"58","author":"W Ball","year":"2011","unstructured":"Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, Williams WG, Schwartz L, Guttman A, Woo A. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58:2313\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"2135_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.112.136085","volume":"127","author":"BJ Maron","year":"2013","unstructured":"Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013;127:585\u201393.","journal-title":"Circulation"},{"key":"2135_CR8","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1161\/01.CIR.0000097110.55312.BF","volume":"108","author":"P Sorajja","year":"2003","unstructured":"Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation. 2003;108:2342\u20138.","journal-title":"Circulation"},{"key":"2135_CR9","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1007\/s00330-018-5951-8","volume":"29","author":"YJ Shin","year":"2019","unstructured":"Shin YJ, Lee JH, Yoo JY, Kim JA, Jeon Y, Yoon YE, Chun EJ. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain. Eur Radiol. 2019;29:4593\u2013602.","journal-title":"Eur Radiol"},{"key":"2135_CR10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jacc.2013.03.055","volume":"62","author":"T Kubo","year":"2013","unstructured":"Kubo T, Kitaoka H, Yamanaka S, Hirota T, Baba Y, Hayashi K, Iiyama T, Kumagai N, Tanioka K, Yamasaki N, Matsumura Y, Furuno T, Sugiura T, Doi YL. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;62:1252\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"2135_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijcard.2016.05.031","volume":"218","author":"DW Kehl","year":"2016","unstructured":"Kehl DW, Buttan A, Siegel RJ, Rader F. Clinical utility of natriuretic peptides and troponins in hypertrophic cardiomyopathy. Int J Cardiol. 2016;218:252\u20138.","journal-title":"Int J Cardiol"},{"key":"2135_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/cvr\/cvv023","volume":"105","author":"JC Tardiff","year":"2015","unstructured":"Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R, Maier LS, Ashrafian H, Huke S, van der Velden J. Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res. 2015;105:457\u201370.","journal-title":"Cardiovasc Res"},{"key":"2135_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cjca.2019.05.035","volume":"5","author":"S He","year":"2019","unstructured":"He S, Wang Z, Cheem TH, Liao H, Chen X, He Y. External validation of the model of thrombo-embolic risk in hypertrophic cardiomyopathy patients. Can J Cardiol. 2019;5:5. https:\/\/doi.org\/10.1016\/j.cjca.2019.05.035 ((in press)).","journal-title":"Can J Cardiol"},{"key":"2135_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cca.2010.12.034","volume":"412","author":"AK Saenger","year":"2011","unstructured":"Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, Giannitsis E, Gustafson S, Handy B, Katus H, Melanson SE, Panteghini M, Venge P, Zorn M, Jarolim P, Bruton D, Jarausch J, Jaffe AS. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta. 2011;412:748\u201354.","journal-title":"Clin Chim Acta"},{"key":"2135_CR15","doi-asserted-by":"publisher","first-page":"h3868","DOI":"10.1136\/bmj.h3868","volume":"351","author":"M Pavlou","year":"2015","unstructured":"Pavlou M, Ambler G, Seaman SR, Guttmann O, Elliott P, King M, Omar RZ. How to develop a more accurate risk prediction model when there are few events. BMJ. 2015;351:h3868.","journal-title":"BMJ"},{"key":"2135_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jjcc.2013.07.008","volume":"63","author":"Y Jenab","year":"2014","unstructured":"Jenab Y, Pourjafari M, Darabi F, Boroumand MA, Zoroufian A, Jalali A. Prevalence and determinants of elevated high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Cardiol. 2014;63:140\u20134.","journal-title":"J Cardiol"},{"key":"2135_CR17","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.amjcard.2015.09.006","volume":"116","author":"C Zhang","year":"2015","unstructured":"Zhang C, Liu R, Yuan J, Cui J, Hu F, Yang W, Zhang Y, Yang C, Qiao S. Significance and determinants of cardiac Troponin I in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015;116:1744\u201351.","journal-title":"Am J Cardiol"},{"key":"2135_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12947-017-0115-6","volume":"15","author":"R Hladij","year":"2017","unstructured":"Hladij R, Rajtar-Salwa R, Dimitrow PP. Troponin as ischemic biomarker is related with all three echocardiographic risk factors for sudden death in hypertrophic cardiomyopathy (ESC Guidelines 2014). Cardiovasc Ultrasound. 2017;15:24.","journal-title":"Cardiovasc Ultrasound"},{"key":"2135_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1253\/circj.CJ-10-0782","volume":"75","author":"T Kubo","year":"2011","unstructured":"Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Baba Y, Hayato K, Yamasaki N, Matsumura Y, Yasuda N, Sugiura T, Doi YL. Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J. 2011;75:919\u201326.","journal-title":"Circ J"},{"key":"2135_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00380-013-0452-9","volume":"30","author":"S Okayama","year":"2015","unstructured":"Okayama S, Soeda T, Kawakami R, Takami Y, Somekawa S, Ueda T, Sugawara Y, Matsumoto T, Sung JH, Nishida T, Uemura S, Saito Y. Evaluation of coronary artery disease and cardiac morphology and function in patients with hypertrophic cardiomyopathy, using cardiac computed tomography. Heart Vessels. 2015;30:28\u201335.","journal-title":"Heart Vessels"},{"key":"2135_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/00004872-200303000-00030","volume":"21","author":"D Rizzoni","year":"2003","unstructured":"Rizzoni D, Palombo C, Porteri E, Muiesan ML, Kozakova M, La Canna G, Nardi M, Guelfi D, Salvetti M, Morizzo C, Vittone F, Rosei EA. Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J Hypertens. 2003;21:625\u201331.","journal-title":"J Hypertens"},{"key":"2135_CR22","doi-asserted-by":"publisher","first-page":"e007161","DOI":"10.1161\/JAHA.117.007161","volume":"6","author":"G Finocchiaro","year":"2017","unstructured":"Finocchiaro G, Magavern E, Sinagra G, Ashley E, Papadakis M, Tome-Esteban M, Sharma S, Olivotto I. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. J Am Heart Assoc. 2017;6:e007161.","journal-title":"J Am Heart Assoc"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02135-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02135-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02135-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T09:03:35Z","timestamp":1625303015000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02135-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2135"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02135-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee on Medical Research of West China Hospital of Sichuan University and conformed to the principles of the Helsinki declaration. The requirement for informed consent was waived because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}